Ventricular Assist Device Implantation and Bariatric Surgery: A Route to Transplantation in Morbidly Obese Patients with End-Stage Heart Failure. Issue 2 (February 2021)

• Record Type: Journal Article
• Authors: Jeng, Eric I.; Miller, Amber H.; Friedman, Jeffrey; Tapia-Ruano, Stephen A.; Reilly, Kevin; Parker, Alex; Vilaro, Juan; Aranda, Juan M.; Klodell, Charles T.; Beaver, Thomas M.; Arnaoutakis, George J.; Ahmed, Mustafa
• Is Part Of: ASAIO journal. Volume 67:Issue 2(2021)
• Publication Date: 2021-02
• Subjects: left ventricular assist device -- morbid obesity -- orthotopic heart transplant -- congestive heart failure -- sleeve gastrectomy; Artificial organs -- Periodicals; 617
• DOI: 10.1097/MAT.0000000000001212
• Languages: English
• ISSNs: 1058-2916

Abstract

Abstract : We reviewed our experience of morbidly obese patients with end-stage heart failure that underwent left ventricular assist device (LVAD) implantation. From January 1, 2008 to January 1, 2018, 240 adult LVADs were implanted at our center. We reviewed the cases of patients presenting with end-stage heart failure and morbid obesity (preoperative body mass index [BMI] ≥ 35 kg/m 2 ) who underwent LVAD-alone, and compared that to a group that underwent LVAD and bariatric surgery (laparoscopic sleeve gastrectomy [LSG]) as a means for weight reduction. Demographic characteristics, perioperative details, BMI, and status of transplant candidacy were recorded. Statistical analysis was performed (SPSS version 25) with χ 2 analysis, Kaplan–Meier survival analysis, regression analysis, and Student's t-test. Twenty-nine patients met criteria and underwent LVAD implantation. Fifteen patients underwent LVAD-alone. Fourteen patients underwent LVAD + LSG. Both groups showed good survival outcomes, LVAD-alone (88.9 ± 5.9 months) versus LVAD +LSG (96.1 ± 12.4 months) but were not significantly different. However, we did note that more patients in the LVAD + LSG group were bridged to heart transplantation ( p < 0.001). LVAD-alone and/or LVAD + LSG are both technically feasible and effective treatment options for the long-term survival of morbidly obese patients with end-stage heart failure. Combining LVAD + LSG can help bridge patients to heart transplantation.